Matulane (procarbazine hydrochloride) / Leadiant Biosci - LARVOL DELTA

Clinical Outcomes of Reduced-Dose Whole-Brain Radiotherapy After Induction Chemotherapy for Primary Central Nervous System Lymphoma: A Retrospective Single-Institution Study (ASTRO 2026) - "Induction chemotherapy consisted of R-MPV (rituximab, methotrexate, procarbazine, and vincristine) up to seven cycles, followed by two cycles of high-dose cytarabine administered as consolidation after radiotherapy. Reduced-dose WBRT following induction chemotherapy provided durable disease control and favorable survival outcomes in a real-world PCNSL cohort. These findings support rdWBRT as an effective consolidative strategy. Further investigation of neurocognitive outcomes is warranted."

Clinical data • Retrospective data • B Cell Lymphoma • CNS Lymphoma • Hematological Malignancies • Lymphoma • Non-Hodgkin’s Lymphoma • Oncology • Primary Central Nervous System Lymphoma

Response-Directed Radiotherapy after Methotrexate-Based Systemic Therapy for Patients with Primary CNS Lymphoma (ASTRO 2026) - "The most common ST regimen was HD-MTX, Procarbazine, and Vincristine (MPV) +/- Rituximab (R) in 32/52 (62%) of pts, while 13/52 (25%) received HD-MTX +/- R, and 7/52 (13%) received other HD-MTX-based regimens. 16/52 pts (31%) received consolidative cytarabine... In pts with PCNSL treated with HD-MTX-based ST, an RT approach incorporating a boost to residual disease is associated with improved PFS. Further investigation into optimal consolidative strategies in pts with a PR following HD-MTX-based induction is warranted."

Clinical • CNS Lymphoma • Eye Cancer • Hematological Malignancies • Lymphoma • Non-Hodgkin’s Lymphoma • Oncology • Primary Central Nervous System Lymphoma • Primary Vitreoretinal Lymphoma • Secondary Central Nervous System Lymphoma

Diagnosis and treatment decision of an IDH-mutant glioma through CSF-based cfDNA sequencing. (PubMed, Neurooncol Adv) - "The patient was initially treated with vorasidenib, an IDH inhibitor, which was then switched to a procarbazine-CCNU chemotherapy due to clinical worsening under initial therapy. CSF-based cfDNA sequencing is a promising tool for minimally invasive diagnosis of tumors of the CNS in situations in which tissue biopsy is challenging or non-informative."

Journal • Brain Cancer • CNS Tumor • Glioma • Oncology • Solid Tumor • IDH1 • TERT

High-Dose Methotrexate Containing Induction Chemotherapy Followed By Nivolumab Consolidation in Older (≥ 65) Patients with Previously Untreated Primary CNS Lymphoma (ASH 2023) - P1 | "Variations of the following regimens were used for induction: 43% R-MPV (rituximab, methotrexate, procarbazine, and vincristine) (43%), 29% MRT (methotrexate, rituximab, and temozolomide), 21% MR (methotrexate and rituximab), and 7% MATRix (methotrexate, cytarabine, thiotepa, and rituximab)... The current study demonstrates encouraging safety and clinical outcomes of nivolumab consolidation in older PCNSL patients who are deemed poor candidates for ASCT or WBI. No DLT was observed during the safety run-in phase, and there was no unexpected toxicity associated with nivolumab although 1 patient discontinued the study treatment due to Stevens-Johnson syndrome, a rare but known AE associated with nivolumab, after Cycle 1. Overall, nivolumab consolidation was associated with favorable survival rates in a group of patients with poor-risk PCNSL."

Clinical • Acute Kidney Injury • CNS Lymphoma • Fatigue • Hematological Disorders • Hematological Malignancies • Infectious Disease • Lymphoma • Nephrology • Neutropenia • Non-Hodgkin’s Lymphoma • Oncology • Primary Central Nervous System Lymphoma • Renal Disease • Septic Shock • Steven-Johnson Syndrome

Successful Autologous Hematopoietic Stem Cell Transplantation in HIV-Associated Primary CNS Lymphoma (SOHO 2026) - "He underwent thiotepa/carmustine-conditioned auto-HSCT with neutrophil engraftment at day +18 and platelet recovery at day +19. This case demonstrates that auto-HSCT is feasible and effective in HIV-associated PCNSL despite profound baseline immunosuppression. It challenges historical contraindications to transplantation in PLWH with CNS disease and supports reconsideration of eligibility criteria for curative-intent therapies and clinical trials. ART: antiretroviral therapy; auto-HSCT: autologous hematopoietic stem cell transplantation; CD: cluster of differentiation; CNS: central nervous system; DLBCL: diffuse large B-cell lymphoma; HIV: human immunodeficiency virus; MATRix: methotrexate, cytarabine, thiotepa, and rituximab; PCNSL: primary CNS lymphoma; PLWH: people living with HIV; R-MPV: rituximab plus high-dose methotrexate, procarbazine, and vincristine."

B Cell Lymphoma • CNS Lymphoma • Diffuse Large B Cell Lymphoma • Hematological Malignancies • Lymphoma • Non-Hodgkin’s Lymphoma • Oncology • Primary Central Nervous System Lymphoma • CD34

Lessons from the IELSG45 trial: The impact of patient fitness on dropout rate in primary central nervous system lymphoma (PCNSL) studies (ASH 2025) - "Patients deemed adequately fit were assigned to receive the standard combination of HDMTX,procarbazine, and rituximab as induction therapy...Patients ineligible for HDMTX wereassigned to receive concomitant whole-brain radiotherapy, temozolomide, and rituximab as inductiontherapy, followed by maintenance temozolomide (Part B)...The 3-year OS was 44 (±16%) forprocarbazine and 54 (±14%) for lenalidomide... Risk of treatment failure (in terms of dropout and survival rates) appeared higher comparedto the PRIMAIN trial. Discrepancies in feasibility and efficacy between PRIMAIN and FIORELLA trialsgenerate some concerns about generalization of results of PCNSL trials among different geographicalregions.These unexpected outcomes offer several valuable lessons on the incorporation of comorbidity indexesinto trial eligibility/stratification and the relevance of interim analyses to inform ethical decisions early."

Clinical • CNS Lymphoma • Hematological Malignancies • Lymphoma • Non-Hodgkin’s Lymphoma • Primary Central Nervous System Lymphoma • Subarachnoid Hemorrhage

Long-Term Follow-Up of the Response-Adapted Intergroup EORTC/LYSA/FIL H10 Trial for Localized Hodgkin Lymphoma. (PubMed, J Clin Oncol) - "Clinical Trial Updates provide an opportunity to disseminate additional results from studies, published in JCO or elsewhere, for which the primary end point has already been reported.The primary analysis of the Early positron emission tomography (ePET) Response-Adapted Treatment in localized Hodgkin Lymphoma H10 Trial demonstrated that in ePET-negative patients, the risk of relapse increased when involved-node radiotherapy (INRT) was omitted and that in ePET-positive patients, switching from doxorubicin, bleomycin, vinblastine, and dacarbazine (ABVD) to bleomycin, etoposide, doxorubicin, cyclophosphamide, vincristine, procarbazine, and prednisone (BEACOPPesc) significantly improved 5-year progression-free survival (PFS). In conclusion, the present long-term analysis confirms that in ePET-negative patients, the omission of INRT is associated with lower 10-year PFS. Instead, in ePET-positive patients, no significant difference between standard and experimental arms emerged..."

Journal • Hematological Malignancies • Hodgkin Lymphoma • Lymphoma • Oncology

Nivolumab+AVD vs eBEACOPP in Advanced-Stage Classic Hodgkin Lymphoma: Single-Center, Nonrandomized, Prospective Clinical Trial (Real Clinical Practice) (SOHO 2026) - "N-AVD resulted in longer progression-free survival than eBEACOPP in adults with advanced-stage cHL and had a better side-effect profile. eBEACOPP: bleomycin, etoposide, doxorubicin, cyclophosphamide, vincristine, procarbazine, and prednisone in escalated doses, ECOG: Eastern Cooperative Oncology Group, HR: hazard ratio, N-AVD: nivolumab plus doxorubicin, vinblastine, and dacarbazine, PET-CT: positron emission tomography-computed tomography."

Clinical • Metastases • Classical Hodgkin Lymphoma • Hematological Malignancies • Hodgkin Lymphoma • Lymphoma • Oncology

Ibrutinib in combination with rituximab, methotrexate, vincristine, and procarbazine (R-MVP/i) for newly diagnosed primary CNS lymphoma (PCNSL). (PubMed, Neuro Oncol) - "R-MVP/i was well tolerated and associated with excellent disease control and survival."

Journal • CNS Lymphoma • Hematological Disorders • Hematological Malignancies • Infectious Disease • Lymphoma • Neutropenia • Non-Hodgkin’s Lymphoma • Oncology • Primary Central Nervous System Lymphoma • Thrombocytopenia • Transplantation

Single-Center Experience with Vorasidenib in Patients with Grade 3 or 4 IDH-Mutant Gliomas (EANO 2026) - "Prior treatments included surgical resection (47, 84%), radiation (45, 80%), temozolomide (44, 78%), ivosidenib (13, 23%), bevacizumab (11, 20%), lomustine (10, 18%), lomustine + procarbazine (7, 13%), and pembrolizumab (4, 7%). In this heavily pre-treated cohort of patients with high-grade IDH mutant gliomas, vorasidenib was well-tolerated and associated with promising 6 and 12-month PFS rates. Optimal role of the agent in the treatment of high-grade gliomas requires prospective evaluation."

Clinical • Anaplastic Astrocytoma • Astrocytoma • Brain Cancer • Glioblastoma • Glioma • High Grade Glioma • Oligodendroglioma • Oncology • Solid Tumor

Patient-Reported Chemotherapy-Induced Peripheral Neuropathy in Advanced-Stage Classic Hodgkin Lymphoma Treated With BrECADD and eBEACOPP: New Data From the HD21 Trial (SOHO 2026) - "Chemotherapy-induced peripheral neuropathy sensory symptoms occurred in both arms during treatment and decreased over FU and were generally less frequent in BrECADD-treated participants. Participants with these symptoms reported poorer overall health. Multiagent regimens for advanced-stage classic HL associated with fewer sensory symptoms may contribute to better overall health."

Clinical • Metastases • Classical Hodgkin Lymphoma • Hematological Malignancies • Hodgkin Lymphoma • Lymphoma • Oncology

THE RANDOMIZED STUDY GHSG HD21 SHOWS SUPERIOR TOLERABILITY AND EFFICACY OF BRECADD VERSUS BEACOPP IN ADVANCED STAGE CLASSICAL HODGKIN LYMPHOMA (EHA 2024) - P3 | "Background:We hypothesized that therapy with the novel BrECADD regimen (brentuximab vedotin, etoposide,cyclophosphamide, doxorubicin, dacarbazine, dexamethasone) guided by positron emission tomography aftertwo cycles (PET2) could improve the treatment of advanced-stage classical Hodgkin lymphoma (AS-cHL). TheHD21 trial aimed at demonstrating superiority over the intensified BEACOPP regimen (bleomycin, etoposide,doxorubicin, cyclophosphamide, vincristine, procarbazine, prednisone) in terms of treatment-related morbidity(TRMB) and non-inferiority (NI) in terms of progression-free survival (PFS)...BrECADD is significantly more effective than BEACOPP and is associated with an unprecedentedly high 4-yearPFS, reducing the risk of progression/relapse by a third. Together with an abbreviated treatment duration forthe majority of patients and a favorable tolerability and feasibility profile, treatment with PET2-individualizedBrECADD sets a new benchmark for the treatment of..."

Clinical • Metastases • Hematological Malignancies • Hodgkin Lymphoma • Lymphoma • Oncology

BRECADD IS NON-INFERIOR TO EBEACOPP IN PATIENTS WITH ADVANCED STAGE CLASSICAL HODGKIN LYMPHOMA: EFFICACY RESULTS OF THE GHSG PHASE III HD21 TRIAL (ICML 2023) - P3 | "The research was funded by: Takeda Oncology Introduction: Individualized, PET2-guided first-line treatment of patients with advanced-stage classical Hodgkin Lymphoma (AS-cHL) with eBEACOPP (bleomycin, etoposide, doxorubicin, cyclophosphamide, vincristine, procarbazine, prednisone) achieves outstanding survival outcomes, but also causes relevant treatment-related morbidity (TRMB). We hypothesized that remodeling the eBEACOPP regimen with brentuximab vedotin (BV) could decrease TRMB while maintaining its high efficacy. Here, we report the results of the HD21 study regarding non-inferiority of BrECADD (BV, etoposide, cyclophosphamide, doxorubicin, dacarbazine, dexamethasone) as compared to eBEACOPP in terms of progression-free survival (PFS)... This interim analysis of the GHSG HD21 trial fully establishes non-inferiority of BrECADD compared to eBEACOPP. Importantly, we observed a relevant reduction in early PFS events with BrECADD resulting in a 3-year PFS rate of..."

Clinical • Late-breaking abstract • Metastases • P3 data • Hematological Malignancies • Hodgkin Lymphoma • Lymphoma • Oncology

Tolerability and efficacy of BrECADD versus BEACOPP in advanced stage classical Hodgkin lymphoma: GHSG HD21, a randomized study. (ASCO 2024) - P3 | "Background: We hypothesized that therapy with the novel BrECADD regimen (brentuximab vedotin, etoposide, cyclophosphamide, doxorubicin, dacarbazine, dexamethasone) guided by positron emission tomography after two cycles (PET2) could improve the treatment of advanced-stage classical Hodgkin lymphoma (AS-cHL). The HD21 trial aimed at demonstrating superiority over the intensified BEACOPP regimen (bleomycin, etoposide, doxorubicin, cyclophosphamide, vincristine, procarbazine, prednisone) in terms of treatment-related morbidity (TRMB) and non-inferiority (NI) in terms of progression-free survival (PFS)... BrECADD is significantly more effective than BEACOPP and is associated with an unprecedentedly high 4-year PFS, reducing the risk of progression, relapse or death by a third. Together with an abbreviated treatment duration of only 3 months for the majority of patients and a favorable tolerability, treatment with PET2-individualized BrECADD sets a new benchmark for the..."

Clinical • Late-breaking abstract • Metastases • Hematological Malignancies • Hodgkin Lymphoma • Lymphoma • Oncology

Determinants of clinical decision-making in first-line treatment of pleomorphic xanthoastrocytoma and the impact of BRAF status on subsequent therapies: a 10-year single-center series (EANO 2026) - "Grade 3 PXA pts underwent multimodality treatment, with 90% (9/10) receiving either radiochemotherapy with concurrent and adjuvant temozolomide (TMZ) (n=6) or radiotherapy followed by TMZ (n=3)...Second-line systemic chemotherapies included TMZ (n=4, mPFS 3.4 months) and fotemustine/lomustine with or without procarbazine (n=3, mPFS 4.5 m). Targeted therapies administered at first or second progression included dabrafenib/trametinib (n=2, DCR 50%, mPFS 25 m), vemurafenib (n=1, DCR 100%, mPFS 27 m), and regorafenib (n=1, DCR 0%, mPFS 1.1 m)... First-line treatment for PXA is primarily driven by grade, extent of resection, and patient-related factors. Despite the high prevalence of BRAF V600E mutations, targeted therapy was utilized in a minority of cases, likely due to the long analysis period and evolving therapeutic standards, including the approval of dabrafenib/trametinib in Italy in 2024 for high-grade gliomas. The clinical impact of BRAF inhibition and its potential..."

Clinical • Astrocytoma • Brain Cancer • High Grade Glioma • Oncology • Pleomorphic Xanthoastrocytoma • BRAF

Pembrolizumab and Chemotherapy in Newly-Diagnosed, Early Unfavorable or Advanced Stage Classic Hodgkin Lymphoma: The Phase 2 Keynote-C11 Study (ASH 2022) - P2 | "Introduction: In a recent study, pembrolizumab followed by doxorubicin, vinblastine, and dacarbazine (AVD) had promising efficacy in patients (pts) with newly-diagnosed, early unfavorable, or advanced-stage classic Hodgkin lymphoma (cHL) (Allen et al...Pts aged ≤60 yrs who were PET3-positive (Deauville score 4-5) received 2-4 cycles of escalated bleomycin plus etoposide, doxorubicin, cyclophosphamide, vincristine, procarbazine, and prednisone (esc BEACOPP, chemotherapy phase 2)... Pembrolizumab induction followed by chemotherapy was well tolerated in pts with newly-diagnosed, early unfavorable, or advanced-stage cHL, with 26% of pts achieving a PET2-negative response following the initial course of pembrolizumab alone and 68% having a PET3-negative response as assessed by investigator following the initial chemotherapy phase. Data from this PET-adapted regimen show promising antitumor activity and no safety concerns mid-treatment, indicating that this regimen may be..."

P2 data • Endocrine Disorders • Hematological Malignancies • Hodgkin Lymphoma • Lymphoma • Oncology

Health-Related Quality of Life of Patients With Advanced-Stage Classic Hodgkin Lymphoma Treated With BrECADD and eBEACOPP: Results From the HD21 Study (SOHO 2026) - "HRQoL improved in both treatment arms during FU. Smaller declines in overall health and fatigue were observed during treatment and greater improvement at various time points during FU in BrECADD. Better long-term functioning was also reported at multiple time points in BrECADD."

Clinical • HEOR • Metastases • Classical Hodgkin Lymphoma • Hematological Malignancies • Hodgkin Lymphoma • Lymphoma • Oncology

Effects of antibiotic prophylaxis in first-line therapy of advanced stage classic Hodgkin lymphoma: An analysis of the GHSG HD21 study (ASH 2025) - "In the GHSG HD21 trial for advanced-stage classic Hodgkin lymphoma (AS-cHL), patients received polychemotherapy regimens (eBEACOPP[bleomycin, etoposide, doxorubicin, cyclophosphamide, vincristine, procarbazine, and prednisone] orBrECADD [brentuximab vedotin, etoposide, cyclophosphamide, doxorubicin, dacarbazine, anddexamethasone]) with a risk to develop febrile neutropenia (FN) and/or infections. This comprehensive analysis of the HD21 trial demonstrates the efficacy of ABP and peg G-CSF in thetreatment of AS-cHL in preventing FN and higher-grade infections. This effect is most pronounced in thefirst cycle and in patients receiving BrECADD. Based on these results, we recommend the use of ABPduring the first cycle of the BrECADD regimen, at least."

Clinical • Metastases • Classical Hodgkin Lymphoma • Febrile Neutropenia • Hematological Malignancies • Hodgkin Lymphoma • Infectious Disease • Lymphoma • Neutropenia

Results of the primary end-point of the LOC-R01: A randomized phase II Study of lenalidomide and ibrutinib in association with rituximab-methotrexate procarbazine vincristin (R-MPV) as a targeted induction treatment for patients aged 18 to 65 with a newly diagnosed primary central nervous system lymphoma (PCNSL) (ASH 2025) - P1/2 | "Background : With standard high-dose methotrexate (HDMTX) and cytarabine (HDAraC)-basedinductions, half of the patients achieved complete response (CR)...Responders received two cycles of HDAraCfollowed by HD thiotepa-busulfan and ASCT... Both arms met the predetermined threshold of efficacy with 86% and 82% of CR/CRurates in the lenalidomide and ibrutinib arm, respectively. R-MPV plus a BTK-inhibitor or animmunomodulatory drug constitutes an interesting first-line induction for PCNSL patients up to 65 years.Correlation of patient, disease and lymphoid subpopulations characteristics with response in eachtreatment arm will be explored to guide the choice of the targeted therapy. Ancillary studies regardingthe prognostic impact of baseline and end of induction levels of cytokines in the CSF, ctDNA inplasma/CSF and radiomic features, as biomarkers of response, are planned."

Clinical • IO biomarker • P2 data • CNS Disorders • CNS Lymphoma • Hematological Malignancies • Hepatology • Lymphoma • Mental Retardation • Non-Hodgkin’s Lymphoma • Primary Central Nervous System Lymphoma • Steven-Johnson Syndrome • CD4 • ICOS • PD-1

Positron Emission Tomography-Adapted Therapy in Bulky Stage I/II Classic Hodgkin Lymphoma: CALGB 50801 (Alliance). (PubMed, J Clin Oncol) - "Our study of PET-adapted therapy in bulky stage I/II cHL met its primary goal and was associated with an excellent 3-year PFS rate of 92.3% in all patients, with the majority being spared radiotherapy and exposure to intensified chemotherapy."

Journal • Cardiovascular • Febrile Neutropenia • Hematological Disorders • Hematological Malignancies • Hodgkin Lymphoma • Infectious Disease • Lymphoma • Neutropenia • Oncology • Septic Shock

Assessing the efficacy and tolerability of PET-guided BrECADD versus eBEACOPP in advanced-stage, classical Hodgkin lymphoma (HD21): a randomised, multicentre, parallel, open-label, phase 3 trial. (PubMed, Lancet) - P3 | "BrECADD guided by PET after two cycles is better tolerated and more effective than eBEACOPP in first-line treatment of adult patients with advanced-stage, classical Hodgkin lymphoma."

Journal • Metastases • P3 data • Hematological Malignancies • Hodgkin Lymphoma • Lymphoma • Oncology

Multicenter Randomized Phase II Study of R-MPV-A Chemoimmunotherapy With or Without Low-Dose Whole-Brain Radiotherapy for Newly-Diagnosed Primary CNS Lymphoma. (PubMed, Neuro Oncol) - "R-MPV-A is a highly efficacious and safe regimen with or without LD-WBRT. LD-WBRT contributes to disease control and increases PFS in PCNSL."

Journal • P2 data • Brain Cancer • CNS Lymphoma • Hematological Malignancies • Lymphoma • Non-Hodgkin’s Lymphoma • Oncology • Primary Central Nervous System Lymphoma

Relapsed/Refractory Hodgkin lymphoma after first-line escalated beacopdac: Adverse outcomes are overcome by use of second-line targeted therapy - an international real-world analysis (ASH 2025) - "The eBEACOPDac regimen, which replaces procarbazine with dacarbazine, isfavoured in some countries due to reduced gonadal and hematologic toxicity, with similar survival rates(Santarsieri, Lancet Oncol 2025)...Most patientsreceived conventional combination 2L chemotherapy (chemo, n=55; 76%), with gemcitibine,dexamethasone and cisplatin (GDP) most frequently used (n=48; 67%). 17 patients (24%) received 2Ltargeted agents: pembro-GVD (n=8), BV-DHAC (n=5), BV-nivo (n=2), pembro-ICE (n=1) and BrentuximabVedotin (BV) monotherapy (n=1)... For R/R HL after 1L eBEACOPDac, patients treated with 2L chemo have inferior outcomes compared topatients who relapse after ABVD. This informs our discussions with patients who relapse after 1LeBEACOPDac when consenting to 2L treatment. The use of 2L targeted agents was associated withsubstantially better outcomes, with a 47% difference in 2-yr PFS, which is unlikely to be attributable todifferences in baseline characteristics alone."

Adverse events • Clinical • Real-world • Real-world evidence • Classical Hodgkin Lymphoma • Hematological Malignancies • Hodgkin Lymphoma • Lymphoma

Timing of autologous stem cell transplantation and induction response in central nervous system lymphoma. (PubMed, Int J Hematol) - "Although high-dose busulfan and thiotepa (BuTT) conditioning followed by autologous stem cell transplantation (ASCT) is a promising consolidation strategy, the optimal timing and real-world outcomes of ASCT remain unclear...Nine patients underwent upfront ASCT shortly after achieving complete remission with rituximab, methotrexate, procarbazine, and vincristine and remained in remission at a median follow-up of 681 days (range, 147-1322 days)...BuTT/ASCT is highly effective when administered promptly after remission, whereas salvage ASCT after multiple therapies is associated with poor outcomes. Timely clinical decision-making and upfront consolidation may be key to optimizing the therapeutic benefits of ASCT in CNSL, although further validation is warranted."

Journal • CNS Lymphoma • Hematological Malignancies • Lymphoma • Non-Hodgkin’s Lymphoma • Oncology • Primary Central Nervous System Lymphoma • Secondary Central Nervous System Lymphoma • Transplantation

Lomustine with or without procarbazine in recurrent glioblastoma-A propensity score matching analysis. (PubMed, Neurooncol Adv) - "Multivariable Cox regression did not reveal significant differences (HR 1.31, 95% CI, 0.90-1.90, P = .166). Our data indicates that potential additive toxicity by intensified combination chemotherapy should be avoided due to lack of efficacy compared to lomustine monotherapy."

Journal • Brain Cancer • Glioblastoma • Oncology • Solid Tumor • MGMT